A Large-Scale Investigation of Hypoxia-Preconditioned Allogeneic Mesenchymal Stem Cells for Myocardial Repair in Non-Human Primates: Paracrine Activity Without Remuscularization

Xinyang Hu1,2, Yinchuan Xu1,2, Zhiwei Zhong1,2, Yan Wu1,2, Jing Zhao1,2, Yingchao Wang1,2, Haifeng Cheng3, Minjian Kong3, Fengjiang Zhang4, Qi Chen4, Jianzhong Sun5, Qian Li5, Jing Jin1,2, Qingju Li1,2, Lihong Chen1,2, Chen Wang1,2, Hongwei Zhan6, Youqi Fan1,2, Qian Yang7, Lei Yu7, Rongrong Wu1,2, Jie Liang1,2, Jinyun Zhu1,2, Ya Wang1,2, Yiping Jin1,2, Yifan Lin1,2, Fan Yang1,2, Liangliang Jia1,2, Wei Zhu1,2, Jinghai Chen1,2,8, Hong Yu1,2, Jianyi Zhang9, Jian’an Wang1,2

1Department of Cardiology, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China; 2Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou, PR China; 3Department of Cardiovascular Surgery, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China; 4Department of Anesthesiology, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China; 5Department of Radiology, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China; 6Department of Nuclear Medicine, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China; 7Department of Ultrasonography, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China; 8Institute of Translational Medicine, Zhejiang University, Hangzhou, PR China, and; 9Department of Biomedical Engineering, University of Alabama at Birmingham, AL, USA

Y.H. and Y.X. contributed equally to this study.

Running title: Hypoxia Preconditioned MSC Therapy for MI

Subject Terms:
Cell Therapy
Stem Cells
Basic Science Research
Myocardial Infarction

Address correspondence to:
Dr. Jian’an Wang
Department of Cardiology,
Provincial Key Lab of Cardiovascular Research
Second Affiliated Hospital
Zhejiang University School of Medicine
Hangzhou 310009, China
Tel: 86 571 87783992
Fax: 86 571 87037885
jian_an_wang@yahoo.com

Dr. Jianyi “Jay” Zhang
Chair, Department of Biomedical Engineering
Professor of Medicine, of Engineering
School of Medicine, School of Engineering
The University of Alabama at Birmingham, UAB
1825 University Blvd, Birmingham, AL 35294
Tel: 205-934-8421
Jayzhang@uab.edu

In December 2015, the average time from submission to first decision for all original research papers submitted to Circulation Research was 13.05 days.
ABSTRACT

**Rationale:** The effectiveness of transplanted bone marrow mesenchymal stem cells (MSCs) for cardiac repair has been limited; thus, strategies for optimizing stem-cell based myocardial therapy are needed.

**Objective:** The present study was designed to test our central hypothesis that hypoxia preconditioned MSCs (HP-MSCs) are more effective than MSCs cultured under ambient oxygen levels (N-MSCs) for the treatment of myocardial injury in a large-scale (N=49), long-term (9 months), non-human primate (Cynomolgous monkeys) investigation.

**Methods and Results:** MSCs were engineered to express green fluorescent protein, cultured under ambient oxygen (N-MSCs) or 0.5% oxygen (HP-MSCs) for 24 hours, and then tested in the infarcted hearts of Cynomolgous monkeys (1×10^7 cells per heart). HP increased the expression of several pro-survival/pro-angiogenic factors in cultured MSCs, and measurements of infarct size and left-ventricular function at Day 90 after myocardial infarction (MI) were significantly more improved in monkeys treated with HP-MSCs than in monkeys treated with the control vehicle; functional improvements in N-MSCs–treated monkeys were not significant. HP-MSCs transplantation was also associated with increases in cardiomyocyte proliferation, vascular density, myocardial glucose uptake, and engraftment of the transplanted cells, and with declines in endogenous cell apoptosis, but did not increase the occurrence of arrhythmogenic complications.

**Conclusions:** HP improved the effectiveness of MSCs transplantation for the treatment of MI in nonhuman primates without increasing the occurrence of arrhythmogenic complications, which suggests that future clinical trials of HP-MSCs transplantation are warranted.

**Keywords:** Mesenchymal stem cells, hypoxia preconditioning, myocardial infarction, Cynomolgous monkeys.
**Nonstandard Abbreviations and Acronyms:**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSCs</td>
<td>Bone marrow mesenchymal stem cells</td>
</tr>
<tr>
<td>HP</td>
<td>Hypoxia preconditioning</td>
</tr>
<tr>
<td>N-MSCs</td>
<td>Normal cultured bone marrow mesenchymal stem cells</td>
</tr>
<tr>
<td>HP-MSCs</td>
<td>Hypoxia preconditioned bone marrow mesenchymal stem cells</td>
</tr>
<tr>
<td>GFP</td>
<td>Green fluorescent protein</td>
</tr>
<tr>
<td>LVEFs</td>
<td>Left ventricular ejection fractions</td>
</tr>
<tr>
<td>NHP</td>
<td>Nonhuman primate model</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco’s Modified Eagle’s Medium</td>
</tr>
<tr>
<td>MI</td>
<td>Myocardial infarction</td>
</tr>
<tr>
<td>ESV</td>
<td>End systolic volume</td>
</tr>
<tr>
<td>FACS</td>
<td>Flow cytometry</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic resonance image</td>
</tr>
<tr>
<td>PET</td>
<td>Positron emission tomography</td>
</tr>
<tr>
<td>SMA</td>
<td>Smooth muscle actin</td>
</tr>
<tr>
<td>EPO</td>
<td>Erythropoietin</td>
</tr>
<tr>
<td>EPOR</td>
<td>Erythropoietin receptor</td>
</tr>
<tr>
<td>ANG1</td>
<td>Angiopoietin-1</td>
</tr>
<tr>
<td>HIF1α</td>
<td>Hypoxia inducible factor 1α</td>
</tr>
<tr>
<td>VEGF</td>
<td>Vascular endothelial growth factor</td>
</tr>
<tr>
<td>HGF</td>
<td>Hepatocyte growth factor</td>
</tr>
<tr>
<td>PDGF-BB</td>
<td>Platelet-derived growth factor BB</td>
</tr>
<tr>
<td>CPT1B</td>
<td>Carnitinepalmitoyl transferase 1B</td>
</tr>
<tr>
<td>THEM2</td>
<td>Thioesterase superfamily member 2</td>
</tr>
<tr>
<td>HK2</td>
<td>Hexokinase 2</td>
</tr>
<tr>
<td>PDK4</td>
<td>Pyruvate dehydrogenase kinase, isozyme 4</td>
</tr>
<tr>
<td>TUNEL</td>
<td>Terminal deoxynucleotidyl transferredUTP nick end labeling</td>
</tr>
</tbody>
</table>
INTRODUCTION

Bone-marrow mesenchymal stem cells (MSCs) have improved cardiac performance when administered after acute myocardial infarction (MI) in both large-animal models and in patients\textsuperscript{1,2}. However, the results from randomized-controlled clinical trials have been less impressive; the authors of one meta-analysis concluded that left-ventricular ejection fractions (LVEFs) increased by just 2.92% in response to cell therapy\textsuperscript{3}. Nevertheless, MSCs remain attractive for the treatment of myocardial disorders, because they are easy to obtain, self-replicating, multi-potent, and only mildly immunogenic after transplantation\textsuperscript{4}. Thus, researchers continue to search for techniques that may improve the efficacy of MSCs therapy.

Only a small percentage of transplanted cells are retained and survive at the site of administration in infarcted myocardial tissue, and this low engraftment rate is believed to be one of the primary barriers to the effectiveness of cell therapy\textsuperscript{5}. However, we have shown that the engraftment rate of MSCs in rodent models of myocardial injury can be improved by incubating the cells under hypoxic conditions before administration\textsuperscript{6,7}, and infarct sizes were significantly smaller in rats treated with hypoxia-preconditioned MSCs (HP-MSCs) than in rats treated with MSCs cultured under ambient (i.e., normoxic) conditions (N-MSCs). HP-MSCs transplantation has also been investigated for the treatment of left-ventricular (LV) remodeling after acute myocardial infarction in pigs\textsuperscript{8}. However, the effect of transplanted HP-MSCs on myocardial recovery has yet to be evaluated in a nonhuman primate (NHP) model.

Although the results from both preclinical and early-phase clinical trials have consistently indicated that MSCs transplantation is safe, only large-animal studies can evaluate a novel therapeutic with enough detail to ensure that patients receive the maximum possible benefit while minimizing the risk of adverse events\textsuperscript{9}. For example, stem-cell–derived cardiomyocytes have not been associated with arrhythmogenic complications in mice, rats, or guinea pigs, but when the dose was scaled for delivery to macaques, the treated animals experienced arrhythmias\textsuperscript{10}. Here, we present the results of the first large-scale, randomized, partially double-blind (for assessments of left ventricular [LV] function and infarct size), preclinical investigation of MSCs therapy for the treatment of cardiac injury in an NHP model. MI was surgically induced in Cynomolgus monkeys, and the animals were treated with HP-MSCs, N-MSCs, or control medium (Dulbecco’s Modified Eagle’s Medium [DMEM]). Our results suggest that treatment with HP-MSCs led to significant improvements in LV function and infarct size.
METHODS

A more detailed description of the experimental methods is available online.

Ethics statement.
Experiments involving live animals were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No.85-23, revised 1996) and were approved by the Institutional Animal Care and Use Committee of Zhejiang University.

HP-MSCs/N-MSCs culture conditions and in-vitro studies.
Cynomolgus monkey MSCs were isolated as described previously and then engineered to express GFP via lentivirus transfection. Hypoxia preconditioning was performed by placing the cells in a well-characterized, finely controlled ProOx-C-chamber system (Biospherix, Redfield, NY, USA) for 24 hours. The oxygen concentration in the chamber was maintained at 0.5%, with a residual gas mixture composed of 5% CO2 and balanced N2. N-MSCs were incubated under 21% oxygen and 5% carbon dioxide for 24 hours in complete culture medium. The effect of hypoxia preconditioning on MSCs multi-potency, tube formation and apoptosis were investigated in vitro.

NHP MI model, treatments, and analyses.
Myocardial infarction was surgically induced in 49 adult Cynomolgus monkeys (male, 5-6 years old, 5-7kg body weight); the monkeys were obtained from Suzhou Xishan Zhongke Laboratory Animal Co., Ltd, which has been certificated by the AAALAC. The animals were anesthetized with intramuscular injections of ketamine (5mg/kg) plus midazolam (0.2mg/kg) and ventilated with room air on an animal ventilator (Matrix model 3000 USA). A left thoracotomy was performed, and the left anterior-descending coronary artery was permanently ligated distal to the first branch with a 4-0 silk suture. Thirty minutes after ligation, animals in the HP-MSCs group were injected with a solution of 1×10⁷ allogeneic HP-MSCs in 1 mL DMEM, animals in the N-MSCs group were injected with 1×10⁷ allogeneic N-MSCs in 1 mL DMEM, and animals in the DMEM group were treated with 1 mL DMEM; the injections were delivered with a 29-gauge syringe to five sites in the peri-infarct region. A fourth group of animals (the Normal group) underwent all surgical procedures except the ligation step and recovered without any of the experimental treatments. Heart function and infarct size were evaluated via cardiac magnetic resonance imaging (MRI), cardiac tissue glucose uptake was evaluated via positron emission tomography, electrical stability was evaluated via continuous telemetric electrocardiographic (ECG) monitoring and programmed electrical stimulation, engraftment was evaluated via quantitative RT-PCR measurements of GFP expression, apoptosis was evaluated via TUNEL staining, and vascular density, arteriole density, proliferation, and endogenous progenitor-cell activation were evaluated via immunofluorescence analyses of marker expression.
Statistical analysis.

All data are presented as mean±standard error of the mean (SEM). Comparisons among groups were analyzed for significance with one-way or two-way analysis of variance (ANOVA). A value of p<0.05 was considered significant. Statistical analyses were performed with Sigmaplot software (version 12.0).

RESULTS

Hypoxia preconditioning does not significantly alter marker expression or differentiation potential in MSCs.

Bone marrow MSCs were isolated from Cynomolgus monkeys, incubated under hypoxic or normoxic conditions as described above, and tested for surface-marker expression and differentiation potential. Both HP-MSCs and N-MSCs expressed MSCs markers, such as CD29, CD90, CD105, and CD166, but did not express markers for haematopoietic cells, such as CD34 and CD45 (Online Figure IA), and HP-and N-MSCs were similarly capable of differentiating into osteogenic, adipogenic, and chondrogenic lineages (Online Figure IB). Thus, we observed no obvious differences between HP-MSCs and N-MSCs in surface-marker expression or differentiation potential.

Hypoxia preconditioning promotes the paracrine activity of cultured MSCs.

Previous studies have shown that BM-MSCs secrete multiple cytokines that promote angiogenesis and survival12; thus, we evaluated the effect of hypoxia preconditioning on pro-survival protein expression in MSCs via Western Blot. Erythropoietin (EPO), hypoxia-inducible factor 1α (HIF1α), and angiopoietin-1 (Ang-1) protein levels were significantly greater in HP-MSCs than in N-MSCs (Online Figures IC-ID). Furthermore, in-vitro tube-formation analyses indicated that tube length was significantly greater when human umbilical-vein endothelial cells (HUVECs) were cultured in conditioned medium collected from HP-MSCs than in medium from N-MSCs (Online Figures IE-ID), and when N-MSCs and HP-MSCs were cultured with serum-free medium under 0.1% oxygen to induce apoptosis, subsequent TUNEL staining assessments indicated that hypoxia preconditioning protected the MSCs from cell death (Online Figures IG-IH). Collectively, these data demonstrated that hypoxia preconditioning may enhance the paracrine activity of MSCs.

HP-MSCs transplantation improves cardiac function in an NHP MI model.

We tested our hypothesis that transplanted HP-MSCs would improve recovery after ischemic myocardial injury in an NHP model (Cynomolgus monkey) of myocardial infarction (MI). A total of 49 monkeys underwent the study protocol and were randomly assigned to treatment with 10 million allogeneic HP-MSCs (HP-MSCs group; n=16, bodyweight: 5.30±0.17 kg), 10 million allogeneic N-MSCs (N-MSCs group; n=16, bodyweight: 5.61±0.15 kg), or DMEM(DMEM group; n=15, bodyweight: 5.36±0.35 kg);animals in the Normal group underwent all surgical procedures except for the permanent ligation step.
(Normal group; n=2, bodyweight: 5.30±0.50 kg). Two animals in the HP-MSCs group, 4 in the N-MSCs group, and 5 in the DMEM group died during or shortly after MI induction and treatment because of ventricular arrhythmia or acute heart failure. Ten animals (4 in the HP-MSCs group and 3 in both the DMEM and N-MSCs groups) were sacrificed on Day 3 after injury for analyses of cell engraftment and histological observations, and 14 animals (4 in the N-MSCs group and 5 in both the DMEM and HP-MSCs group) were sacrificed on Day 28 after injury for cardiac functional and histological analyses. Ten of 12(83.3%) animals in the HP-MSCs group, 9 of 13 (69.2%) in the N-MSCs group, and 7 of 12 (58.3%) in the DMEM group survived for at least 28 days after MI, and no animals died from day 28 to day 270 (Figures 1A-1B; Online Figure II). Thus, the survival rate appeared to be higher among animals in the HP-MSCs group than in N-MSCs or DMEM animals, although the number of animals included in the study was not great enough to determine whether the differences between groups were significant.

Cardiac function was measured via MRI assessments of left-ventricular ejection fraction (LVEF) and end-systolic volume (ESV) performed 1 day before injury and 3 days, 28 days, and 90 days afterward. LVEF was unchanged (or slightly smaller) on Day 28 and Day 90 than on Day 3 in DMEM and N-MSCs animals, but measurements in the HP-MSCs group increased significantly from Day 3 to Day 90 (Figure 1C); furthermore, the change in LVEF (ΔLVEF) from Day 3 to Day 28 and from Day 3 to Day 90 was significantly greater in the HP-MSCs group, but not in N-MSCs animals, than in animals treated with DMEM (Figure 1D). ESV measurements increased significantly from Day 3 to Day 90 in the DMEM and N-MSCs groups, but were unchanged in HP-MSCs animals, and ΔESV was significantly smaller in HP-MSCs hearts than in DMEM or N-MSCs hearts from Day 3 to Day 28 (p<0.05), which suggests that HP-MSCs transplantation limited cardiac dilatation (Figures 1E-1F). HP-MSCs transplantation also appeared to be associated with smaller scar sizes at Day 28 after injury (Figure 1G), and measurements of the change in infarct size (ΔIS) indicated that scar size improved significantly more in HP-MSCs hearts than in either DMEM or N-MSCs hearts from Day 3 to Day 28. ΔIS from Day 3 to Day 90 was also better in the HP-MSCs group than in either DMEM or N-MSCs animals, but the differences between groups did not reach statistical significance (Figure 1H). Collectively, these results indicated that HP-MSCs are more effective than N-MSCs for promoting the recovery of cardiac performance and for limiting adverse remodeling after myocardial injury in nonhuman primates.

Measurements of LVEF at later time points (Day 270) tended to be more improved in HP-MSCs animals (Day 3 to Day 270, ΔLVEF=2.81±1.87) than in N-MSCs animals (Day 3 to Day 270, ΔLVEF=−0.21±3.35), but the difference between groups was not significant, likely because the number of animals evaluated for each group (HP-MSCs: n=5, N-MSCs: n=3, Day 270) was small. Day 270 measurements are not reported for the DMEM group, because only two animals were available. Assessments will continue to be performed over longer follow-up periods in all remaining animals.
HP-MSCs transplantation is not associated with arrhythmogenic complications.

Spontaneous arrhythmogenesis is one of the primary risks associated with stem cell therapy for the treatment of cardiac disorders; however, the results from recent large-animal studies have been inconsistent. Arrhythmogenic complications were observed after 1 billion stem-cell–derived cardiomyocytes were delivered to the infarcted hearts of macaques\textsuperscript{10}, but not when 10 million stem-cell–derived cardiomyocytes were administered in a swine MI model\textsuperscript{13}. Thus, we examined whether the hypoxia preconditioning protocol used here might influence the onset of cardiac arrhythmia by continuously monitoring the ECGs of 2 animals in the DMEM group, 4 animals in the N-MSCs group, and 3 animals in the HP-MSCs group from shortly after MI injury until Day 28 for evidence of spontaneous arrhythmogenic complications, including premature ventricular contractions (PVCs) and non-sustained ventricular tachycardia (NSVT). ECGs for the HP-MSCs animals were essentially normal throughout the entire follow-up period, while spontaneous arrhythmias were observed during the acute recovery phase (i.e., between Day 0 and Day 14) for animals in both the DMEM and N-MSCs groups, but not at later time points (Figures 2A-2C). Furthermore, measurements of the effective refractory period and the ventricular fibrillation threshold on day 28 after MI in all three groups were similar (Figures 2D-2F). Taken together, these observations suggest that MSCs treated with the hypoxia preconditioning protocol used for the experiments described in this report do not impair the electromechanical stability of monkey hearts.

**HP-MSCs are engrafted and survive after transplantation into the hearts of nonhuman primates with MI.**

The efficacy of myocardial cell therapy is believed to be limited by the exceptionally small number of transplanted cells that become engrafted and continue to survive at the site of administration\textsuperscript{14}; thus, we tested whether hypoxia preconditioning may improve the engraftment/survival of transplanted MSCs. Because the MSCs were genetically engineered to express GFP, transplanted cells were identified in myocardial tissues from cell-treated animals via immunofluorescence staining for GFP expression, and the engraftment rate was calculated via quantitative PCR measurements of GFP DNA. Clusters of MSCs were observed in the border zone of ischemia on Day 3 after transplantation (Figure 3A), and the engraftment rate was approximately 20-fold greater for HP-MSCs (0.87±0.22%) than for N-MSCs (0.045±0.010%). Measurements in other organs indicated that the majority of injected cells became sequestered in the lungs and liver (Online Figure III). By Day 28, the engraftment/survival rate had declined by at least two orders of magnitude in both groups (HP-MSCs: 0.0013±0.00061%, N-MSCs: 0.00045±0.00015%)(Figures 3B-3D).

Both HP-MSCs and N-MSCs transplantation reduce cardiac apoptosis after MI.

Because so few transplanted cells survived through Day 28, we investigated whether the improvements associated with HP-MSCs transplantation occurred through the cells’ paracrine activity. The potential activation of cardioprotective mechanisms was evaluated by quantifying the number of apoptotic cells in the hearts of animals sacrificed 3 days after MI and cell transplantation. Both HP-MSCs and N-MSCs administration were associated with significant declines in the number of apoptotic cells at the border zone.
of the infarct(Figures 4A-4E); apoptotic cells also tended to be less common in hearts from the HP-MSCs group than in N-MSCs–treated hearts, but not significantly, and hearts from HP-MSCs animals expressed higher levels of the pro-survival proteins HGF, EPO, and Ang-1(Figure 4F). Furthermore, few CD4⁺ or CD8⁺ T lymphocytes were found in the infarcted and border zone regions of hearts (Figures 4G-4N), and the number of T lymphocytes in the hearts of DMEM-, N-MSCs–, and HP-MSCs–treated animals did not differ significantly (Figures 4O-4P), which suggests that the low rates of engraftment and survival were not caused by immune rejection of the transplanted cells. Thus, our observations indicate that HP-MSCs transplantation improved the survival of native cardiac cells, perhaps by activating endogenous cytoprotective mechanisms, and are consistent with previous reports that suggest MSCs are immune-privileged cells15.

**HP-MSCs transplantation enhances cardiomyocyte proliferation after MI.**

Proliferating cells were identified via immunofluorescent staining for the proliferation marker Ki67. Four weeks after injury, Ki67⁺ cells were significantly more common in the border zone of HP-MSCs–treated hearts than in the border zones of hearts from DMEM and N-MSCs animals (Figures 5A-5E), while cells that expressed both Ki67 and Troponin I were significantly more common in the HP-MSCs group than in the DMEM group (Figures 5A-5D, 5F). Thus, HP-MSCs transplantation appeared to promote the proliferation of endogenous cardiac cells, including cardiomyocytes. To determine whether the effect of HP-MSCs transplantation on cardiomyocyte proliferation (and other paracrine mechanisms) could have been mediated by the activation of cardiac progenitor cells, which are stimulated by MSCs transplantation in infarcted swine hearts16, expression of the progenitor-cell marker c-kit was evaluated in the hearts of animals sacrificed 28 days after MI injury and treatment. Border-zone c-kit⁺ cells tended to be most prevalent in HP-MSCs–treated hearts, but the differences between groups did not reach statistical significance (Inline Figures IVA-IVD).

**HP-MSCs transplantation promotes the angiogenic response to MI.**

To determine whether increases in vessel growth could have contributed to the functional improvements observed in HP-MSCs–treated hearts17, cells that expressed the endothelial-cell marker CD31 or smooth-muscle actin (SMA) were identified in the border zone of infarction 4 weeks after injury. CD31⁺ and SMA⁺ cells were significantly more common in HP-MSCs–treated hearts than in hearts treated with either N-MSCs or DMEM (Figures 5G-5J, 5O and Figures 5K-5N, 5P). Collectively, these observations suggest that hypoxia preconditioning can promote the ability of MSCs to stimulate angiogenesis in native myocardial tissues.

**HP-MSCs transplantation modulates myocardial metabolism after MI.**

The progressive decline in myocardial performance that often occurs after myocardial injury has been linked to adverse changes in myocardial metabolism, and the results from a recent study suggest that the functional improvements associated with HP-MSCs transplantation in the hearts of rats are accompanied
by metabolic improvements. To determine whether HP-MSCs can also improve the metabolic profile of injured nonhuman primate hearts, we evaluated glucose uptake in the hearts of HP-MSCs, N-MSCs, and DMEM animals via [(18F)-fluoro-D-glucose Positron Emission Tomography (18F-FDG PET); measurements were performed in the infarct zone, the border zone of the infarct, and in uninjured regions (i.e., the remote zone) of the hearts 4 weeks after MI injury (Figure 6A). Myocardial glucose uptake was significantly higher in the border zone of hearts from animals in the HP-MSCs group than in the border zones of hearts from DMEM and N-MSCs animals, but measurements in the infarcted and remote zones of all three treatment groups were similar (Figure 6B). Furthermore, Western blot analyses indicated that the expression of proteins involved in fatty acid metabolism (CPT1B, THEM2) or in the inhibition of glucose metabolism (PDK4) declined significantly in the remote zone, but not in the border zone, of HP-MSCs–treated hearts on Day 28 after MI (Figures 6C-6F). Collectively, these observations demonstrate that HP-MSCs transplantation increases the viability of ischemic myocardium by modulating cardiac energy supply and metabolism.

**HP-MSCs transplantation alters the expression of inflammatory and chemo-inducible proteins after MI.**

To gain new insight into which paracrine factors and molecular mechanisms may contribute to the beneficial effects associated with HP-MSCs transplantation in injured nonhuman primate hearts, quantitative proteomics analyses were performed with tissues from the peri-infarcted regions of hearts from HP-MSCs, N-MSCs, and DMEM animals sacrificed 3 days after injury. The expression of numerous inflammatory and/or chemo-inducible proteins, such as CCL24, CCL26, IL-16, IL-1RA, M-CSF, MCP-2 and NT-3, declined substantially in response to HP-MSCs transplantation (Figures 7A-7L), and these observations were corroborated by ELISA measurements of IL-1α, IL-16, and MCP-2 levels (Online Figures VA-VC). HP-MSCs–treated hearts also tended to have the fewest number of cells that expressed the macrophage marker CD68, but the differences between groups did not reach statistical significance (Figures 7M-7N). Collectively, these observations suggested that the functional benefits associated with cell therapy appear to be accompanied by a decline in myocardial inflammation.

**DISCUSSION**

Although the safety and feasibility of MSCs transplantation for treatment of ischemic myocardial disease has been well documented in both preclinical and early-phase clinical trials, improvements in myocardial function have been unremarkable. Nevertheless, MSCs are easy to obtain, can be readily maintained and expanded in culture, and modulate the immune system, which may have a beneficial effect on the inflammatory response to myocardial injury and cell administration. Thus, researchers continue to search for techniques that may improve the effectiveness of MSCs therapy. Hypoxia preconditioning is among the most promising techniques being tested, because it stimulates paracrine mechanisms that may improve the survival, migration, and angiogenic activity of transplanted MSCs while avoiding the safety concerns associated with genetic or pharmacological approaches.
potential benefit of hypoxia preconditioning is also supported by the results from our recently completed, phase I, randomized-controlled CHINA-AMI trial\textsuperscript{25}; however, studies in an NHP model are needed to adequately characterize the safety profile and mechanisms of action associated with HP-MSCs therapy before these cells can be administered to large numbers of patients.

Here, we present the first large-scale (\(N=49\)) investigation of HP-MSCs administration for the treatment of MI in an NHP model. Our results suggest that hypoxia preconditioning substantially improved the therapeutic potency of MSCs: improvements in infarct size and LVEF from Day 3 to Day 28 or Day 90 were significantly greater in HP-MSCs–treated monkeys than in monkeys treated with N-MSCs or DMEM, while differences between the N-MSCs and DMEM groups did not reach statistical significance. Furthermore, the observed improvements were not accompanied by evidence of MSCs differentiation, and less than 1\% of the administered cells were engrafted by the native myocardium, which is consistent with the results from a number of other studies\textsuperscript{26-28} and suggests that the benefit of HP-MSCs transplantation occurred through the cells’ paracrine activity, rather than through remuscularization of the infarcted region\textsuperscript{10, 29}. Our observations also illustrate the exceptionally low immunogenicity of MSCs, because neither N-MSCs nor HP-MSCs administration was associated with increases in the number of T-lymphocytes or macrophages at the site of administration, despite the cells’ allogeneic origin and the absence of concomitant immunosuppressive therapy.

**Hypoxia preconditioning and MSCs engraftment.**

MSCs reside in the bone marrow, where oxygen levels are low, which suggests that MSCs may have an intrinsic tolerance for the oxygen-deprived microenvironment of ischemic myocardium. Furthermore, previous reports indicate that HP-MSCs are less likely than N-MSCs to be rejected by the immune systems of rats\textsuperscript{30, 31}, and our results indicate that hypoxia preconditioning increases MSCs migration and reduces MSCs apoptosis when the cells are cultured under 0.5\% oxygen\textsuperscript{20}. Thus, the \(\sim 20\)-fold increase in engraftment associated with hypoxia preconditioning observed on Day 3 could have evolved through declines in the host animal’s immune response, increases in cell survival or, perhaps, because the number of cells that were lost to the peripheral circulation declined. However, HP-MSCs engraftment declined to just 0.0013\% by Day 28, which suggests that the beneficial effects associated with hypoxia preconditioning endure far longer than the initial (Day 3) improvement in engraftment.

**Mechanistic observations.**

Because the engraftment rates for N-MSCs and HP-MSCs were low, and we found no evidence to suggest that the transplanted cells differentiated into functional myocytes or endothelial cells, the benefit of HP-MSCs transplantation likely evolved through the secretion of paracrine factors that stimulated endogenous cytoprotective or regenerative mechanisms. The results presented here, as well as in our previous small-animal studies\textsuperscript{6, 7}, confirm that hypoxia preconditioning increases the production of cytokines such as HIF-1, Ang-1, and EPO in MSCs, and HP-MSCs transplantation increased proliferation and angiogenesis, while limiting fibrosis (i.e., infarct size) and the expression of a panel of inflammatory...
proteins in the native myocardial tissue. Furthermore, although hypoxia preconditioning has been shown to reduce glucose uptake in MSCs, myocardial glucose uptake increased significantly at the border-zone of the infarct in response to HP-MSCs transplantation, which may protect against progressive LV dysfunction and dilatation, while fatty acid metabolism significantly declined in non-infarcted tissues. Notably, the effect of hypoxia preconditioning on MSCs-induced paracrine activity would have been most prominent during the first few days after administration, when the engraftment rate was ~20-fold higher in HP-MSCs animals than in the N-MSCs group. Thus, the improvements in angiogenesis, proliferation, and glucose/fatty acid utilization observed in HP-MSCs animals on Day 28, after the engraftment rates in the two cell-treatment groups had declined by two orders of magnitude, are consistent with current concepts that emphasize the importance of cytokine activity during the early phase of recovery from myocardial injury.

**Arrhythmogenic complications**

Arrhythmogenesis has been recognized as a prominent safety concern of myocardial cell therapy since the complication was first reported in clinical investigations with skeletal myoblasts. Arrhythmia has rarely been reported in small-animal studies, but when human embryonic stem cells were differentiated into cardiomyocytes (hESC-CMs) and administered to the hearts of macaques with ischemia-reperfusion injury, all four of the cell-treated animals experienced periods of premature ventricular contractions and/or tachycardia within two weeks after treatment administration. The authors suggested that this apparent discrepancy between small- and large-animal studies may have been caused, at least in part, by the number of cells (1 billion) administered to the macaques. This exceptionally large dose produced grafts of transplanted cells that were at least 10-fold larger than the grafts observed in other species and, consequently, may have altered electronic signal transduction (re-entry concern). Thus, our present study was conducted with a much smaller cell dose (10 million cells/animal), which did not produce grafts of significant size. Furthermore, experiments in a rat MI model have shown that the conditioned medium from HP-MSCs, but not N-MSCs, can restore conduction velocity and prevent death due to arrhythmia, perhaps by reducing the formation of fibrotic tissue, and the effect of HP-MSCs transplantation on fibrotic tissue formation was also evident in our current investigation, because infarct sizes were significantly more improved in HP-MSCs–treated animals than in animals from the N-MSCs group at Day 28. Collectively, the results presented here suggest that MSCs can be administered to nonhuman primates with no apparent increase in the risk for arrhythmia, and that this observation may be attributable both to the number of cells administered and to the paracrine activity of the HP-MSCs.

**Study limitations.**

The long-term studies associated with this investigation are ongoing. Thus, the outcome assessments related to structural and molecular changes, are not reported for the time course of Day 270 after MI and treatment. Furthermore, although the number of animals included was large compared to other studies in nonhuman primates, previous rodent studies have been performed with much larger study groups, which may explain why animals in the N-MSCs group did not display the level of improvement that is typically...
associated with intramyocardial MSCs transplantation. Our study also omitted the standard clinical regimen of medical treatments for MI and, consequently, the therapeutic effect of MSCs transplantation in patients may differ from the observations reported here.

Conclusions.

In conclusion, this report presents the first large-scale preclinical investigation of HP-MSCs therapy for the treatment of myocardial injury in nonhuman primates. Our results suggest that treatment with HP-MSCs led to significant improvements in cardiac function and infarct size without increasing the risk for arrhythmogenic complications, and that these benefits were likely mediated by increases in the paracrine activity of the hypoxia-preconditioned cells. Collectively, these observations suggest that HP-MSCs transplantation can be feasibly and safely investigated in clinical trials of myocardial cell therapy.

SOURCES OF FUNDING
This work was supported by the National Basic Research Program of China (973 Program, No.2014CB965100, 2014CB965103), National High-tech R&D 863 Program (No.2013AA020101), grants from National Natural Science Foundation of China (No.31171418, 81320108003, 31371498 for JW, No. 81170308, 81370247 for XYH, No. 81500176 for YCX), Science and Technology Department of Zhejiang province public welfare projects (No.2013C37054), Zhejiang province key science and technology innovation team(No.2010R50047).

DISCLOSURES
None.
REFERENCES


FIGURE LEGENDS

**Figure 1.** HP-MSCs transplantation improves cardiac function after MI. (A) Schematic representation of the study design and schedule of events. (B) Number and disposition of animals in each experimental group. Sudden Death: death caused by lethal ventricular tachycardia during the open-chest operation; HF: heart failure; SH: short term (i.e., Day 3) histological assessments; G: GFP immunostaining; TNL: TUNEL staining; MRI: magnetic resonance imaging; PET: positron emission tomography; EP: electrophysiology. (C) MRI assessments of left-ventricular ejection fraction (LVEF) were performed at the indicated time points, and (D) the change in LVEF (ΔLVEF) was calculated by subtracting measurements taken on Day 3 after MI from measurements taken on Day 28 and Day 90. (E) MRI assessments of left-ventricular end-systolic volume (ESV) were performed at the indicated time points. (F) The change in ESV (ΔESV) was calculated by subtracting measurements taken on Day 3 after MI from measurements taken on Day 28 and Day 90. (G) MRI assessments of infarct size were performed at the indicated time points, and (H) the change in infarct size (ΔInfarct Size) was calculated by subtracting measurements taken on Day 3 after MI from measurements taken on Day 28 and Day 90.

**Figure 2.** HP-MSCs transplantation is not associated with arrhythmogenic complications. Electrocardiograms for animals in the HP-MSCs, N-MSCs, and DMEM-treatment groups were monitored continuously (via telemetry) for evidence of (A) premature ventricular contractions or non-sustained ventricular tachycardia (NSVT); representative tracings from a separate study (in macaques) are displayed. (B-C) The average number of (B) premature ventricular contractions and (C) NSVT for animals in each treatment group was calculated daily from the moment of injury until Day 28 afterward. (D-F) Programmed electrical stimulation experiments were performed on Day 28 after MI to determine (E) the effective refractory period (ERP) and (F) the ventricular fibrillation threshold (VFT) for animals in each treatment group.

**Figure 3.** MSCs are engrafted by the native myocardium after transplantation into the hearts of nonhuman primates with MI. (A) Engrafted cells were identified in sections stained for the presence of GFP. The myocardium was visualized via fluorescent immunostaining for TnI, and nuclei were counterstained with Hoechst 33258, bar=50μm; a representative image from the heart of an HP-MSCs-treated animal sacrificed 3 days after MI injury is displayed. (B-D) The number of transplanted cells that were incorporated by the hearts of N-MSCs– and HP-MSCs–treated animals on Day 3 and Day 28 after injury was determined via quantitative, PCR measurements of GFP mRNA levels in samples from the apex of the heart and presented as (B) a percentage of the total number of cells administered and (C-D) the number of cells per gram of heart tissue on (C) Day 3 and (D) Day 28 after MI and treatment.

**Figure 4.** MSCs transplantation reduces cardiac apoptosis after MI. (A-D) Apoptotic cells were identified on Day 3 after MI and treatment via TUNEL staining (red) in (A) sections of noninfarcted tissue from the right ventricle (RV) of animals in the HP-MSCs group and in sections from the border zone of the infarction in hearts from animals in the (B) DMEM, (C) N-MSCs, and (D) HP-MSCs groups. Cardiac tissue was visualized via fluorescent immunostaining for TnI (green), and nuclei were counterstained with...
Hoechst 33258; bar=50 μm. (E) Apoptosis was quantified as the percentage of cells that were positive for TUNEL staining. (F) Expression of the prosurvival proteins including hepatocyte growth factor (HGF), erythropoietin (EPO), and angiopoietin 1 (Ang1) on Day 3 after injury were evaluated in tissues from the border-zone of infarction via Western blot. β-actin levels were also evaluated to serve as a control, and protein levels were quantified via densitometry analysis. (G-N) Immune cells were identified on Day 3 after MI by staining for (G-J) CD4 or (K-N) CD8 expression (brown) in (G, K) sections of noninfarcted tissue from the right ventricle (RV) of animals in the HP-MSCs group and in sections from the border zone of infarction in hearts from animals in the (H, L) DMEM, (I, M) N-MSCs, and (J, N) HP-MSCs groups (bar=100 μm). (O-P) The immune response to cell transplantation was quantified as the percentage of the surface area that stained positively for (O) CD4 and (P) CD8.

Figure 5. HP-MSCs transplantation promotes cardiomyocyte proliferation and angiogenesis after MI. (A-D) Proliferating cells were identified on Day 28 after MI and treatment by staining for expression of the proliferation marker Ki67 (red) in (A) sections of noninfarcted tissue from the right ventricle (RV) of animals in the HP-MSCs group and in sections from the border zone of the infarct in hearts from animals in the (B) DMEM, (C) N-MSCs, and (D) HP-MSCs groups. Cardiac tissue was visualized via fluorescent immunostaining for TnI (green), and nuclei were counterstained with Hoechst 33258 (bar=100 μm); the boxed regions of merged images are also displayed at higher magnification (yellow bar=50 μm). (E) Proliferation was quantified as the number of Ki67+ cells per high-power field (HPF), and (F) cardiomyocyte proliferation was quantified as the number of cells that expressed both Ki67 and TnI per HPF. (G-J) Endothelial cells were identified on Day 28 after MI and treatment by staining for expression of the endothelial marker CD31 (red) in (G) sections of noninfarcted tissue from the right ventricle (RV) of animals in the HP-MSCs group and in sections from the border zone of the infarct in hearts from animals in the (H) DMEM, (I) N-MSCs, and (J) HP-MSCs groups; nuclei were counterstained with Hoechst 33258 (bar=100 μm). (K-N) Smooth-muscle cells were identified on Day 28 after MI and treatment by staining for expression of smooth-muscle actin (SMA) (red) in (K) sections of noninfarcted tissue from the right ventricle (RV) of animals in the HP-MSCs group and in sections from the border zone of the infarct in hearts from animals in the (L) DMEM, (M) N-MSCs, and (N) HP-MSCs groups; nuclei were counterstained with Hoechst 33258 (bar=100 μm). (O) Vascular density was quantified as the number of CD31+ cells per HPF, and (P) arteriole density was quantified as the number of SMA+ cells per HPF.

Figure 6. HP-MSCs transplantation modulates myocardial metabolism after MI. (A) On Day 28 after MI and treatment, animals in the DMEM-, N-MSCs, and HP-MSCs–treatment groups were injected with radiolabeled glucose (18F Fludeoxyglucose), and their hearts were imaged via positron-emission tomography. Data are presented as a bulls-eye image; regions with high glucose uptake appear bright yellow, and images with low glucose uptake appear blue. (B) Glucose uptake was quantified in the infarcted region, at the border-zone of the infarct, and in the noninfarcted (i.e., remote) region of the heart. (C-F) Expression of the metabolic proteins CPT1B, THEM2, HK2, and PDK4 on Day 28 after MI and treatment was evaluated in tissues from (C) the border-zone of infarction and (E) the remote (noninfarcted) zone via Western blot. β-actin levels were also evaluated to serve as a control. Protein levels in (D) the border-zone of infarction and (F) the remote (noninfarcted) zone were quantified via densitometry analysis.
Figure 7. HP-MSCs transplantation modulates the protein expression profile in nonhuman primate hearts with MI. (A-L) Protein array analyses were performed with tissues from the border zone of infarction in animals sacrificed 3 days after MI and treatment. Results are displayed for 16 inflammatory factors and/or chemo-inducible proteins whose expression levels were lower in samples from HP-MSCs–treated hearts than in DMEM-treated heart samples. (M) Inflammation was evaluated on Day 3 after MI by staining for expression of the macrophage marker CD68 (brown) in sections of noninfarcted tissue from the right ventricle (RV) of animals in the HP-MSCs group and in sections from the border zone of infarction in hearts from animals in the DMEM, N-MSCs, and HP-MSCs groups (bar=100 μm). (N) Macrophage infiltration was quantified as the percentage of the surface area that stained positively for CD68.
NOVELTY AND SIGNIFICANCE

What Is Known?

- Results of several clinical trials suggest that the transplantation of bone marrow mesenchymal stem cells (MSCs) for cardiac repair is safe, although their efficacy remains uncertain.

- Studies in rodents and swine indicate that hypoxic preconditioning (HP) can increase the therapeutic effectiveness of transplanted bone marrow MSCs for the treatment of myocardial infarction (MI).

What New Information Does This Article Contribute?

- Hypoxia preconditioning promotes the engraftment of injected MSCs in infarcted hearts of monkeys.

- Cardiac function was significantly improved 90 days after MI injury and treatment with HP-MSCs.

- HP-MSCs transplantation was associated with increases in vascular density and myocardial glucose uptake, and with declines in endogenous-cell apoptosis.

- HP-MSCs transplantation enhanced the proliferation of endogenous cardiomyocytes.

- HP-MSCs transplantation was not associated with arrhythmogenic complications.

MSCs are a promising agent for the treatment of myocardial disorders, because they are easy to obtain, self-replicating, multi-potent, and only mildly immunogenic after transplantation, but their effectiveness in randomized-controlled clinical trials has been disappointing. Therefore researchers continue to develop strategies to improve the therapeutic potency of transplanted MSCs. Here, we present results of our large-scale (N=49), long-term (9 months) investigation of HP-MSCs transplantation in a Cynomolgus monkeys MI model. Hypoxia preconditioning promoted the engraftment of transplanted MSCs, and improvements in heart function after injury and treatment were significantly greater in HP-MSCs–treated monkeys than in monkeys treated with N-MSCs or the control vehicle. HP-MSCs transplantation was also associated with increases in cardiomyocyte proliferation, vascular density, and myocardial glucose uptake, and with declines in endogenous-cell apoptosis, but not with an increase in the occurrence of arrhythmogenic complications. Collectively, these findings support future clinical investigations of HP-MSCs transplantation.
Figure 2

A

Premature Ventricular Contractions (PVCs)

Non-sustained Ventricular Tachycardia (NSVT)

B

Number of Premature Ventricular Contractions

C

Number of NSVT

D

Days after cell injection

Stimulation

Ventricular Fibrillation

E

ERP (ms)

F

VFT (V)

Days after cell injection

DMEM

N-MSC

HP-MSC

DMEM

N-MSC

HP-MSC
Figure 3

A

B

C

D

Engrafted Cell Number / g Heart Weight (Day 3)

Engrafted Cell Number / g Heart Weight (Day 28)

N-MSC  HP-MSC

N-MSC  HP-MSC
Figure 5
Figure 6

A

DMEM  N-MSC  HP-MSC

HEAD  HEAD  HEAD

RIGHT  ANT  LEFT

LEFT  FEET  FEET

B

FDG uptake %

DMEM  N-MSC  HP-MSC

Infarct Zone  Border Zone  Remote Zone

p=0.013  p=0.009  p=0.457

C

PDK4  HK2  β-actin  THEM2  β-actin  CPT1B  β-actin

DMEM  N-MSC  HP-MSC

Day 28 Border Zone

D

Protein/β-actin

DMEM  N-MSC  HP-MSC

CPT1B  THEM2  HK2  PDK4

Day 28 Border Zone

E

PDK4  HK2  β-actin  THEM2  β-actin  CPT1B  β-actin

DMEM  N-MSC  HP-MSC

Day 28 Remote Zone

F

Protein/β-actin

DMEM  N-MSC  HP-MSC

CPT1B  THEM2  HK2  PDK4

Day 28 Remote Zone

p<0.001  p<0.001  p<0.001  p<0.001

p=0.002  p<0.001  p<0.001

p=0.015  p=0.961  p=0.156
A Large-Scale Investigation of Hypoxia-Preconditioned Allogeneic Mesenchymal Stem Cells for Myocardial Repair in Non-Human Primates: Paracrine Activity Without Remuscularization

Xinyang Hu, Yinchuan Xu, Zhiwei Zhong, Yan Wu, Jing Zhao, Yingchao Wang, Haifeng Cheng, Minjian Kong, Fengjiang Zhang, Qi Chen, Jianzhong Sun, Qian Li, Jing Jin, Qingju Li, Lihong Chen, Chen Wang, Hongwei Zhan, Youqi Fan, Qian Yang, Lei Yu, Rongrong Wu, Jie Liang, Jinyun Zhu, Ya Wang, Yipeng Jin, Yifan Lin, Fan Yang, Liangliang Jia, Wei Zhu, Jinghai Chen, Hong Yu, Jianyi Zhang and Jian'an Wang

Circ Res. published online January 19, 2016;
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/early/2016/01/19/CIRCRESAHA.115.307516
Free via Open Access

Data Supplement (unedited) at:
http://circres.ahajournals.org/content/suppl/2016/01/19/CIRCRESAHA.115.307516.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/
ONLINE SUPPLEMENTAL DATA

Mesenchymal stem cells (MSCs) isolation and culture
MSCs were isolated and harvested as described previously\(^1\). Briefly, bone marrow was harvested via posterior iliac crest puncture or repeated washing of the tibia cavity; then, the aspirate was centrifuged at 1000 rpm for 5 min. The cell-containing pellets were resuspended in Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), plated on 10 cm dishes, and cultured at 37 °C in a humidified atmosphere containing 21% oxygen and 5% carbon dioxide for 24 hours. The non-adherent cells were removed and the adherent cells were washed 3 times with phosphate buffered saline (PBS) and cultured in complete culture medium (DMEM plus 10% fetal bovine serum); the culture medium was refreshed every 3-4 days. The MSCs became confluent after 1 week of culture and were passaged after using trypsin-EDTA for cell mobilization. Cells were passaged four to eight times before use in subsequent experiments.

Green Fluorescent Protein (GFP) lentiviral transfection
MSCs were engineered to express GFP via lentivirus transfection as described previously\(^2\). Briefly, lentivirus particles for LV-GFP mock vectors were purchased from GeneChem, Shanghai. Culture medium (500 μL) containing 100 MOI lentivirus particles was added to 5×10⁵ MSCs in T25 flask for 8 hours, the medium was increased to 1 mL for another 8 hours, and then the culture medium was refreshed. Transfection efficacy was evaluated after 72 hours of transduction by flow-cytometry.

Hypoxia and normoxia preconditioning protocols
MSCs were plated at a density of 1×10⁵ cells/cm² in complete culture medium (DMEM plus 10% fetal bovine serum). Hypoxia preconditioning was performed in a well-characterized, finely controlled ProOx-C-chamber system (Biospherix, Redfield, NY, USA) for 24 hours. The oxygen concentration in the chamber was maintained at 0.5%, with a residual gas mixture composed of 5% CO₂ and balanced N₂. Normoxia-preconditioned MSCs were incubated under 21% oxygen and 5% carbon dioxide for 24 hours in complete culture medium.

Flow cytometry (FACS) analysis
MSCs were detached from the plate, stained at room temperature for 1 hour with fluorescent antibodies against the indicated cell surface markers (CD133/2-PE MACS130090853; CD34-PE MACS130081002; CD309 MACS130093598; Anti-human CD105 eBioscience12-1057-42; Anti-human CD90 eBioscience17-0909; Anti-human CD117 eBioscience12-1178-42; Anti-human CD29 eBioscience12-0299-71; Anti-human CD45 eBioscience11-0459-42; PE Mouse Anti-human CD166 BD560903), and washed 3 times with PBS. Surface marker expression was evaluated with a flow cytometer and FACSCount II software. Assessments were also performed with isotype-matched antibodies to control for non-specific staining (Mouse IgG1-PE MACS130092212; Mouse IgG2-PE MACS130091835; Mouse IgG1-APC MACS130092214).

Evaluation of MSCs multi-potency
MSCs multipotency was evaluated via the following adipogenesis, osteogenesis, and chondrogenesis differentiation protocols:\(^3\):

Adipogenesis differentiation: MSCs were seeded at density of 2×10⁵ per well, cultured until confluent, and then treated with the adipogenesis induction medium (DMEM base medium, 10% FBS, penicillin/streptomycin solution [10,000 IU/10,000 IU/100 mL], 1 M dexamethasone [Sigma, Cat. No. D-8893], 0.2 Mm indomethacin [Sigma, Cat. No. I-5879], 0.1 mg/mL insulin [Sigma, Cat.No. I-0516]) for 72 hours and with adipogenic maintenance medium for another 24
hours. The treatment cycle was repeated 4 times, and then the cells were cultured for one additional week in adipogenic maintenance medium (DMEM basemedium, 10% FCS, penicillin/streptomycin solution [10,000 IU/10,000 IU/100 mL] and 0.1 mg/mL insulin), fixed with ice-cold formalin (4%), and incubated with 0.2% Oil Red O solution for 20 min to visualize the formation of fat vacuoles. Images were captured under a light microscope.

**Osteogenesis differentiation:** Cells were seeded in a six-well plate (2×10^5 cells/well), cultured until confluent, and then treated with osteogenesis induction medium for 3 weeks; the medium consisted of DMEM, 10% FBS, penicillin/streptomycin solution, 10^-7 M dexamethasone, 10 mM β glycerophosphate, and 50 uM vitamin C and was changed every 3 days. Osteogenesis differentiation was evaluated with an alkaline phosphatase color development kit (Sidansai) as directed by the manufacturer's instructions. Images were captured under a light microscope.

**Chondrogenesis differentiation:** Cells were seeded in a six-well plate (2×10^5 cells/well), cultured until confluent, treated with chondrogenic induction medium consisting of DMEM, 10% FBS, penicillin/streptomycin solution, 10^-7 M dexamethasone, 10 ng/mL TGF-β and 50 uM vitamin C for 21 days, fixed in 4% paraformaldehyde for 5 min, and then incubated with 1mg/mL Toluidine Blue for 30 min. The excess stain was washed away with double distilled water, and images were captured under a light microscope.

**In vitro tube formation assay**
HP-MSCs or N-MSCs (1×10^6 cells/well) were seeded in 6-well plates, incubated for 24 hours at 37 °C, and centrifuged; then, the conditioned medium was collected. The wells of a 96-well plate were coated with growth factor-reduced Matrigel (BD, San Jose, CA, USA), and human umbilical-vein endothelial cells (HUVECs) were seeded with the HP-MSCs–conditioned medium or the N-MSCs–conditioned medium at a density of 2×10^4 cells/well. Four hours later, images were obtained for five randomly selected fields per well with a phase-contrast microscope (original magnification, 200×), and tube length was quantified with Image-Pro Plus 6.0 software.

**In vitro apoptosis evaluation**
MSCs were plated on 24-well plates (1×10^5 cells/well), cultured under serum starvation and 0.5% oxygen for 24 hours, and then TUNEL stained with an in situ cell death detection kit as directed by the manufacturer's instructions.

**Western Blotting**
Proteins were isolated from cells or heart tissues with RIPA lysis buffer; then, 20 μg of protein per sample was separated via gel electrophoresis, transferred to a poly-vinylidene fluoride membrane, and blocked with 5% milk for 1 hour. The membrane was incubated overnight with primary antibodies against erythropoietin (EPO), the erythropoietin receptor (EPOR), angiopoietin-1 (Ang-1), hypoxia inducible factor 1α (HIF-1α), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), platelet-derived growth factor BB (PDGF-BB), carnitine palmitoyl transferase 1B (CPT1B), thioesterase superfamily member 2 (THEM2), hexokinase 2 (HK2), and pyruvate dehydrogenase kinase isozyme 4 (PDK4); then, the membranes were incubated with HRP-conjugated secondary antibodies at room temperature for 2 hours and exposed via enhanced chemi-luminescence.

**Non-human primate MI model**
Myocardial infarction was surgically induced in 49 adult Cynomolgus monkeys (male; 5-6 years old; 5-7kg body weight) that had been obtained from Suzhou XishanZhongke Laboratory Animal Co.Ltd, which has been certificated by the AAALAC. The animals were anesthetized with intramuscular injections of ketamine (5mg/kg) plus midazolam (0.2mg/kg) and ventilated with
room air on an animal ventilator (Matrix model 3000 USA), then, a left thoracotomy was performed, and the left anterior-descending coronary artery was permanently ligated distal to the first branch with a 4-0 silk suture. MI induction was verified by ST segment elevation and loss of color in the region below the ligation area. Monkeys in the Normal group underwent all surgical procedures except for the permanent ligation step. The chest was closed in layers, and the animals were allowed recover. Post-operative analgesia was provided with morphine, and penicillin was used to prevent post-operative infection.

**Cell preparation and transplantation**

MSCs were engineered to express GFP 3 days before injection, detached from the plates, centrifuged, washed with PBS, centrifuged again, suspended in serum-free medium (1×10^7 cells/mL), and then cultured under hypoxic or normoxic conditions (as described above). Thirty minutes after MI induction, animals in the HP-MSCs group were treated with a solution of 1×10^7 HP-MSCs in 1 mL DMEM, animals in the N-MSCs group were treated with 1×10^7 N-MSCs in 1 mL DMEM, and animals in the DMEM group were treated with 1 mL DMEM. The treatments were delivered to five sites (2×10^6 cells/site) in the peri-infarct region via direct injection with a 29-gauge syringe.

**Cardiac magnetic resonance imaging (MRI)**

MRI was performed with a 1.5 Tesla clinical scanner (Siemens Aera, Siemens Medical Systems, Islen NJ), a phased-array 4-channel surface coil, and ECG gating as described previously. Animals were anesthetized with intramuscular injections of xylazine (1mg/kg) and ketamine (10mg/kg). After losing consciousness, the monkeys were placed in a supine position within the scanner, and cardiac function (ejection fraction, end-systolic volume, and end-diastolic volume) was analyzed with MR myocardial analysis software (SIMENS) as directed by the manufacturer’s instructions. The MRI sequence parameters were as follows: repetition time = 29.43 ms, flip angle = 50°, field of view = 180 mm × 147mm. To cover the entire ventricle, 7-8 consecutive 6.0-mm slices with a gap of 1.2 mm were planned in the short axis view perpendicular to the horizontal short axis (4-chamber) and vertical long axis (2-chamber) of the left ventricle. The recovery of cardiac function was calculated by subtracting LVEF and ESV measurements taken on Day 3 after injury from measurements taken on Day 28, Day 90, and Day 270. Infarct size was measured via delayed enhancement MRI and quantified with the following formula:

\[
\text{infarct size} = \left( \frac{\text{planimetered endocardial circumferences of the infarcted area} + \text{planimetered epicardial circumferences of the infarcted area}}{\text{total endocardial circumferences}+ \text{total epicardial circumferences}} \right) \times 100\%
\]

All data were analyzed in a double blind fashion.

**Cardiac positron emission tomography (PET)**

Monkeys were intravenously injected with 18F-fludeoxy glucose (FDG), anesthetized 30 min later with intramuscular injections of xylazine (1mg/kg) and ketamine (10mg/kg), and placed in a spread prone position on a dedicated holder for imaging; then, static data was acquired for 15 min in three-dimensional mode with a PET-CT scanner (Siemens BiographTruePoint PET-CT, syngo MMWP VE52A, Siemens Medical Systems, Erlangen, Germany). Images were reconstructed and corrected for attenuation and decay (maximum a posteriori algorithm), dead time, and random scattering; then, transaxial, coronal, and sagittal tomographic slices were obtained. Contiguous 4-7 transaxial sections that contained distinct infarcted regions of the left ventricle were used for semi-quantitative evaluation; the region of interest (ROI) method was used to measure the standard uptake value (SUV) of the infarcted region, peri-infarct region, and normal region. Results were presented as a bulls eye image, where the infarcted region
appeared dark blue, the remote zone appeared light orange or yellow, and the peri-infarct zone was defined as the boundary between the infarct and remote zones.

**Telemetric monitoring**
ECG recordings were continuously acquired from conscious monkeys with a telemetry system provided by Zande Co.Ltd. The telemetry device was implanted subcutaneously below the apex immediately after MI induction, and ECG recordings were obtained continuously for 30 days and evaluated for evidence of ventricular tachycardia, including premature ventricular contractions (PVCs) and non-sustained ventricular tachycardia (NVST). PVCs were defined as near occurrence of a wide QRS complex and missing p wave, and NSVTs were defined as three or more consecutive PVCs and that terminated spontaneously. ECG data was evaluated by a cardiologist in a double-blind fashion; both the total number and frequency of PVCs and NSVTs were calculated.

**Electrophysiologic study**
Electrophysiological testing was performed via programmed electrical stimulation as described previously. A standard quadripolar electrode catheter (Biosense Webster, MN, USA) was maneuvered through the right internal jugular vein and positioned in the right ventricle, and stimulation was performed at the right ventricular apex. A pacing train of 8 stimuli (S1, 300-400 ms) was delivered, followed by 1 (S2) or 2 (S2 and S3) additional (premature) stimuli at sequentially shorter coupling intervals until the ventricular effective refractory period (ERP) was reached and ventricular tachycardia was induced. For ventricular fibrillation threshold testing, concomitant high frequency stimulation was initiated at 0.5 V and increased in increments of 0.1 V until ventricular fibrillation was induced.

**Quantitative PCR**
The number of cells that were engrafted by the heart or became sequestered in other organs was determined via quantitative polymerase chain reaction (qPCR) assessments of GFP DNA levels. Genomic DNA was prepared from cells and tissues by using the TAKARA MiNiBEST Universal Genomic DNA Extraction Kit (Cat: #9765, TAKARA BIOTECHNOLOGY CO., Dalian, China). The purified DNA was amplified by using SYBR Premix Ex Taq (Cat: #RR420, TAKARA BIOTECHNOLOGY CO., Dalian, China), and the exogenous GFP gene was amplified to serve as a reference for calculating the number of MSCs. Absolute standard curves were generated for each batch of MSCs, and the specificity of GFP amplification was demonstrated by measuring the DNA in 10-fold diluted (5.5×10³ to 1.8×10⁶) cell populations. Amplification was performed with GFP forward (5' GCGAGAAGATCATCCCCGTG 3') and reverse (5' ACTTCTGGTTCTTGCGGTCG 3') primers, and the procedure consisted of an initial 5-min denaturation step at 95°C followed by 40 amplification cycles. Each amplification cycle consisted of a 10-s denaturation period at 95°C followed by a 30-s annealing and elongation period at 72°C. After amplification, DNA melting curves were generated by denaturing at 95°C for 15 s, cooling to 60°C for 1 minute, and then increasing the temperature to 95°C at a rate of 0.5°C/s while continuously monitoring fluorescence. Cell engraftment was quantified as the number of GFP-positive cells per gram of apex heart tissue, and the engraftment rate was calculated according to the following formula:

\[
\text{cell engraftment rate} = \frac{\text{(number of GFP-positive cells per gram of apex heart tissue)} \times (\text{mass of apex heart tissue})}{(2 \times 10^6)} \times 100\%.
\]

**Immunofluorescence analyses**
Monkeys were euthanized via direct intramyocardial injection of potassium chloride, and the hearts were removed immediately. The LV tissue was cut vertically into 6 rings (R1-R6), and
each ring was sequentially cut into 8 or 9 samples (S1-S9). S3 and S4 of R3 and R4 (i.e., from the site of cell and/or DMEM administration) were collected and embedded for cryosectioning. Tissue sections were frozen, fixed for 10 minutes with 10% formalin and for 15 minutes with 0.2% triton-X100, blocked for 1 hour with 3% bovine serum, incubated overnight with primary antibodies against GFP, CD31, smooth-muscle actin (SMA), Ki67, c-kit, troponin I (Tnl) CD4, CD8, and CD68 (GFP: Novus NB600-308; CD31: abcam ab9498; SMA: abcam ab5694; Ki67: abcam ab66155; c-kit: abcam ab11289; Tnl: abcam ab47003; CD4: Zhongshan Jinqiao ZA-0519; CD8: Zhongshan Jinqiao ZA-0508; CD68: Zhongshan Jinqiao ZM-0060), and then incubated for 1 hour at room temperature with the corresponding secondary antibodies (Donkey Anti-Mouse IgG: abcam ab96876, DyLight® 550; Donkey Anti-Rabbit IgG: abcam ab96892, DyLight® 550; Donkey Anti-Mouse IgG: abcam ab96875, DyLight® 488; Donkey Anti-Rabbit IgG: abcam ab98488, DyLight® 488). Nuclei were counterstained with Hoechst 33258, and the sections were viewed under a fluorescent microscope. Positively stained cells were counted in three sections per heart, ten high-power fields (HPFs) per section. Vascular density was quantified as the number of CD31+ vessels per HPF, arteriole density was quantified as the number of SMA+ vessels per HPF, proliferation was quantified as the number of Ki67+ cells per HPF, cardiac progenitor cells were quantified as the number of c-kit+ cells per HPF, and inflammatory cells were quantified as the percentage of surface area that was positive for CD4, CD8, or CD68. For assessments of apoptosis, frozen and fixed sections were TUNEL-stained, nuclei were counterstained with Hoechst 33258, and the sections were viewed under a fluorescent microscope. TUNEL+ cells and Hoechst+ nuclei were counted in three sections per heart, ten high-power fields (HPFs) per section, and apoptosis was quantified as the percentage of TUNEL+ cells.

Proteomics analysis
Protein samples were prepared from left ventricular peri-infarct tissues. Briefly, frozen LV tissue was placed in liquid nitrogen, ground into a very fine powder with a mortar and pestle, and treated with RIPA buffer for 1 hour at 4 °C; then, the mixture was centrifuged at 13000 rpm for 30 min at 4 °C, and the supernatants were collected for analysis by Capitalbio Corporation. The samples were loaded with a smart-arrayer machine and reacted with growth factor protein array (RayBio Human cytokine antibody array G-Series 1000 [Cat# AAH-CYT-G1000-4] containing 80 growth factors); the signal was scanned with a Luxscan 10K-A machine and analyzed with Spot data software.

ELISA Assay
Proteins were isolated from homogenized cardiac tissues with RIPA lysis buffer; then, IL-1α, IL-16 and MCP-2 concentrations were measured with a monkey ELISA kit (Shanghai Meilian Biology Technology Limited Company, Shanghai, China) as directed by the manufacturer's instructions. Protein levels were expressed as a fraction of the total protein concentration.
REFERENCES


Online Figure I

A

<table>
<thead>
<tr>
<th>Surface Marker</th>
<th>N-MSC</th>
<th>HP-MSC</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD29</td>
<td>97.1%</td>
<td>96.6%</td>
</tr>
<tr>
<td>CD34</td>
<td>0.3%</td>
<td>0.2%</td>
</tr>
<tr>
<td>CD45</td>
<td>0.3%</td>
<td>0.2%</td>
</tr>
<tr>
<td>CD90</td>
<td>98.7%</td>
<td>93.6%</td>
</tr>
<tr>
<td>CD105</td>
<td>98.6%</td>
<td>96.2%</td>
</tr>
<tr>
<td>CD117</td>
<td>0.3%</td>
<td>0.1%</td>
</tr>
<tr>
<td>CD133</td>
<td>0.3%</td>
<td>0.4%</td>
</tr>
<tr>
<td>CD166</td>
<td>94.2%</td>
<td>95.7%</td>
</tr>
<tr>
<td>CD309</td>
<td>0.1%</td>
<td>0.6%</td>
</tr>
<tr>
<td>MSCA-1</td>
<td>0.6%</td>
<td>0.9%</td>
</tr>
<tr>
<td>Lin-</td>
<td>99.4%</td>
<td>98.3%</td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th></th>
<th>Adipocytes</th>
<th>Osteoblasts</th>
<th>Chondroblasts</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-MSC</td>
<td><img src="image1" alt="Image" /></td>
<td><img src="image2" alt="Image" /></td>
<td><img src="image3" alt="Image" /></td>
</tr>
<tr>
<td>HP-MSC</td>
<td><img src="image4" alt="Image" /></td>
<td><img src="image5" alt="Image" /></td>
<td><img src="image6" alt="Image" /></td>
</tr>
</tbody>
</table>

C

<table>
<thead>
<tr>
<th>Protein</th>
<th>N-MSC</th>
<th>HP-MSC</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEGF</td>
<td><img src="image7" alt="Image" /></td>
<td><img src="image8" alt="Image" /></td>
</tr>
<tr>
<td>EPO</td>
<td><img src="image9" alt="Image" /></td>
<td><img src="image10" alt="Image" /></td>
</tr>
<tr>
<td>EPOR</td>
<td><img src="image11" alt="Image" /></td>
<td><img src="image12" alt="Image" /></td>
</tr>
<tr>
<td>HIF-1α</td>
<td><img src="image13" alt="Image" /></td>
<td><img src="image14" alt="Image" /></td>
</tr>
<tr>
<td>Ang1</td>
<td><img src="image15" alt="Image" /></td>
<td><img src="image16" alt="Image" /></td>
</tr>
<tr>
<td>PDGF-BB</td>
<td><img src="image17" alt="Image" /></td>
<td><img src="image18" alt="Image" /></td>
</tr>
<tr>
<td>β-actin</td>
<td><img src="image19" alt="Image" /></td>
<td><img src="image20" alt="Image" /></td>
</tr>
</tbody>
</table>

D

<table>
<thead>
<tr>
<th>Protein</th>
<th>N-MSC</th>
<th>HP-MSC</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEGF</td>
<td><img src="image21" alt="Image" /></td>
<td><img src="image22" alt="Image" /></td>
</tr>
<tr>
<td>EPO</td>
<td><img src="image23" alt="Image" /></td>
<td><img src="image24" alt="Image" /></td>
</tr>
<tr>
<td>EPOR</td>
<td><img src="image25" alt="Image" /></td>
<td><img src="image26" alt="Image" /></td>
</tr>
<tr>
<td>HIF-1α</td>
<td><img src="image27" alt="Image" /></td>
<td><img src="image28" alt="Image" /></td>
</tr>
<tr>
<td>Ang1</td>
<td><img src="image29" alt="Image" /></td>
<td><img src="image30" alt="Image" /></td>
</tr>
<tr>
<td>PDGF-BB</td>
<td><img src="image31" alt="Image" /></td>
<td><img src="image32" alt="Image" /></td>
</tr>
</tbody>
</table>

E

<table>
<thead>
<tr>
<th></th>
<th>N-MSC</th>
<th>HP-MSC</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image33" alt="Image" /></td>
<td><img src="image34" alt="Image" /></td>
<td></td>
</tr>
</tbody>
</table>

F

<table>
<thead>
<tr>
<th></th>
<th>N-MSC</th>
<th>HP-MSC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tube length (um)</td>
<td><img src="image35" alt="Image" /></td>
<td><img src="image36" alt="Image" /></td>
</tr>
</tbody>
</table>

G

<table>
<thead>
<tr>
<th></th>
<th>N-MSC</th>
<th>HP-MSC</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image37" alt="Image" /></td>
<td><img src="image38" alt="Image" /></td>
<td></td>
</tr>
</tbody>
</table>

H

<table>
<thead>
<tr>
<th></th>
<th>N-MSC</th>
<th>HP-MSC</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image39" alt="Image" /></td>
<td><img src="image40" alt="Image" /></td>
<td></td>
</tr>
</tbody>
</table>

Note: The images and graphs are placeholders and should be replaced with actual images and data.
Online Figure II

Survival Rate%

- Normal
- DMEM
- N-MSC
- HP-MSC

Days
ONLINE FIGURE LEGENDS

Online Figure I. Hypoxia preconditioning enhances paracrine-factor secretion, pro-angiogenic activity, and survival in cultured MSCs.
MSCs were cultured under 0.5% oxygen and 5% carbon dioxide for 24 hours (hypoxia, HP-MSCs) or under ambient conditions (normoxia, N-MSCs). (A) Surface-marker expression was evaluated via flow cytometry. (B) HP-MSCs and N-MSCs were differentiated via established protocols for generating adipocytes (left), osteocytes (center), or chondrocytes (right); then, fat vacuoles were visualized in adipocytes with Oil Red O, osteocytes were evaluated with an alkaline phosphatase color development kit, and chondrocytes were stained with toluidine blue. Images were obtained with a light microscope (bar=100 μm).(C) Expression of the prosurvival proteins VEGF, EPO, EPOR, HIF-1α, Ang-1, and PDGF-BB was evaluated via Western blot. β-actin levels were also evaluated to serve as a control, and (D) protein levels were quantified via densitometry analysis.(E) HUVECs were seeded into the wells of Matrigel-coated plates, cultured for 4 hours in media collected from HP-MSCs or N-MSCs, and viewed under a phase-contrast microscope (bar=100μm).(F) Tube formation was quantified as the summed length of tubes per field. (bar=100μm). (G) HP-MSCs and N-MSCs were cultured under serum starvation and 0.5% oxygen for 24 hours and then TUNEL stained (bar=200 μm). (H) Apoptosis was quantified as the percentage of TUNEL-positive cells.

Online Figure II. Survival after MI was highest in HP-MSCs–treated monkeys (comparisons between groups were not significant).
Myocardial infarction was surgically induced on Day 0 by permanently ligating the left anterior descending coronary artery, and then the animals were randomly assigned to treatment with 10 million HP-MSCs, 10 million N-MSCs, or the delivery vehicle (DMEM); animals in the Normal group underwent all surgical procedures except the ligation step. The number of surviving animals was recorded for each day of the study period.

Online Figure III. Most transplanted MSCs exited the site of administration.
The number of transplanted N-MSCs and HP-MSCs that exited the site of administration and collected in the (A) liver, (B) lungs, (C) kidneys, and (D) spleen was determined via quantitative PCR measurements of GFP DNA levels.

Online Figure IV. Activation of native cardiac progenitor cells was highest in HP-MSCs–treated monkeys (comparisons between groups were not significant).
Sections were collected from the border-zone of infarction in the hearts of (A) DMEM–, (B) N-MSCs–, and (C) HP-MSCs–treated animals on Day 28 after injury and stained for expression of the progenitor-cell marker c-kit (red); cardiomyocytes were visualized by staining for troponin I (TnI, green), and nuclei were counterstained with Hoechst 33258 (blue); bar=100 μm. (D) Progenitor-cell activation was quantified as the number of c-kit–positive cells.

Online Figure V. Expression of inflammatory factors tended to be lowest HP-MSCs–treated monkeys (comparisons between groups were not significant).
Tissues were collected from the border-zone of infarction in the hearts of DMEM–, N-MSCs–, and HP-MSCs–treated animals on Day 3 after injury; then, the levels of (A) macrophage/monocyte chemotactic protein 2 (MCP-2), (B) interleukin-1α (IL-1α), and (C) interleukin-16 (IL-16) were evaluated via ELISA.